Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313-327 and 432-443 of Hepatitis C Virus E1E2 Glycoproteins

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Liu, Ruyu ^a,b   Rao, Huiying ^a,b   Wang, Jianghua ^a,b   Xie, Xingwang ^a,b   Jiang, Dong ^a,b   Pan, Xiaoben ^a,b   Zhao, Ping ^c   Zhang, Henghui ^a,b   Wei, Lai ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; VIRAL CLEARANCE; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; AMINO ACIDS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CELLS, CULTURED; DEMOGRAPHY; EPITOPES; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDES; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 84879477644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066872     Document Type: Article

References (41)

1. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 5: 558-567.
2. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, et al. (2012) Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A.
3. Rosnoblet C, Fritzinger B, Legrand D, Launay H, Wieruszeski JM, et al. (2012) Hepatitis C Virus NS5B and Host Cyclophilin A share a common binding site on NS5A. Journal of Biological Chemistry.
4. Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, et al. (2012) Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut.
5. Kopp M, Murray CL, Jones CT, Rice CM, (2009) Genetic Analysis of the Carboxy-Terminal Region of the Hepatitis C Virus Core Protein. Journal of Virology 84: 1666-1673.
6. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79: 11095-11104.
7. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, et al. (2009) Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 16: 75-90.
8. Simmonds P, (2001) The origin and evolution of hepatitis viruses in humans. J Gen Virol 82: 693-712.
9. Tarr AW, Owsianka AM, Jayaraj D, Brown RJP, Hickling TP, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virusneutralizing monoclonal antibody AP33. Journal of General Virology 88: 2991-3001.
10. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, et al. (2003) Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55: 362-369.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics 41: 1100-U1174.
13. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics. 41: 1105-U1181.
14. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, et al. (2005) The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54: 1157-1161.
15. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, et al. (2006) Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43: 563-572.
16. Rehermann B, Nascimbeni M, (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
17. Bowen DG, Walker CM, (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952.
18. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395-1406.
19. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 104: 6025-6030.
20. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, et al. (2005) Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79: 6023-6034.
21. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. Journal of Biological Chemistry 281: 18285-18295.
22. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413.
23. Keck ZY, Op de Beeck A, Hadlock KG, Xia JM, Li TK, et al. (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. Journal of Virology 78: 9224-9232.
24. Meunier JC, Russell RS, Goossens V, Priem S, Walter H, et al. (2008) Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. Journal of Virology 82: 966-973.
25. Patel AH, Owsianka A, Tarr AW, Juttla VS, Lavillette D, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. Journal of Virology 79: 11095-11104.
26. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, et al. (2007) Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104: 16269-16274.
27. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25-27.
28. Diamond MS, Keck Z-y, Xia J, Wang Y, Wang W, et al. (2012) Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. Plos Pathogens 8: e1002653.
29. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, et al. (2012) Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 86: 2739-2749.
30. Petit MA, Ndongo N, Rechoum Y, De Sequeira S, Zoulim F, et al. (2009) Inhibition of the Binding of HCV Serum Particles to Human Hepatocytes by E1E2-Specific D32.10 Monoclonal Antibody. Journal of Medical Virology 81: 1726-1733.
31. Ndongo N, Berthillon P, Pradat P, Vieux C, Bordes I, et al. (2010) Association of Anti-E1E2 Antibodies with Spontaneous Recovery or Sustained Viral Response to Therapy in Patients Infected with Hepatitis C Virus. Hepatology 52: 1531-1542.
32. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proceedings of the National Academy of Sciences of the United States of America 100: 7271-7276.
33. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, et al. (2012) Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. Plos Pathogens 8: e1002895.
34. Torresi J, Fischer A, Grollo L, Zeng W, Drummer H, et al. (2007) Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunology and Cell Biology 85: 169-173.
35. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH, (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82: 1877-1883.
36. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, et al. (1993) Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. Journal of Clinical Microbiology 31: 1493-1503.
37. Dietzschold B, Gore M, Marchadier D, Niu HS, Bunschoten HM, et al. (1990) Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol 64: 3804-3809.
38. Bartosch B, Dubuisson J, Cosset FL, (2003) Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes. Journal of Experimental Medicine 197: 633-642.
39. Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, et al. (2011) Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol 85: 2793-2802.
40. Song H, Li J, Shi S, Yan L, Zhuang H, et al. (2010) Thermal stability and inactivation of hepatitis C virus grown in cell culture. Virology Journal 7: 40.
41. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106: 7537-7541.